ECM Weekly (2nd July 2023) - Tryt, J&T Express, Redox, Kelun, 4Paradigm, SIA, M&A Research, Walsin
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
396 Views
Kelun-Biotech (科伦博泰) IPO: Fairly Valued at Best
Kelun-biotech, a China-based biopharmaceutical company, launched a deal to raise up to US$200m via a Hong Kong listing. We provide quick thoughts...
517 Views
ECM Weekly (11th June 2023) - Alibaba, Tencent, PDD, Redox, Amman, Kotak, Infratil, Skymark
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
406 Views
Kelun-Biotech (科伦博泰) Pre-IPO: Thoughts on Valuation
Kelun Biotech is raising up to US$400m to list in Hong Kong. In this note we provide valuation for its core products, SKB264 and A166.
456 Views
China Healthcare Weekly (Apr.28) - Four Stages of China Biotech, The Real Foothold of R&D, Kelun
The real foothold of pharmaceutical company is “Development” rather than “Research”. China biotech will go through four stages: 2015-2019, 2019...
398 Views